↓ Skip to main content

Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience

Overview of attention for article published in The Journal of Headache and Pain, July 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
7 news outlets
twitter
1 X user
facebook
2 Facebook pages

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience
Published in
The Journal of Headache and Pain, July 2015
DOI 10.1186/s10194-015-0551-3
Pubmed ID
Authors

Antonio Russo, Alessandro Tessitore, Francesca Conte, Laura Marcuccio, Alfonso Giordano, Gioacchino Tedeschi

Abstract

Transcutaneous supraorbital neurostimulation (tSNS) has been recently found superior to sham stimulation for episodic migraine prevention in a randomized trial. We evaluated both the safety and efficacy of a brief period of tSNS in a group of patients with migraine without aura (MwoA). We enrolled 24 consecutive patients with MwoA experiencing a low frequency of attacks, which had never taken migraine preventive drugs in the course of their life. Patients performed a high frequency tSNS and were considered "compliant" if they used the tSNS for ≥ 2/3 of the total time expected. For this reason, four patients were excluded from the final statistical analysis. Primary outcome measures were the reduction migraine attacks and migraine days per month (p < 0.05). Furthermore, we evaluated the percentage of patients having at least 50 % reduction of monthly migraine attacks and migraine days. Secondary outcome measures were the reduction of headache severity during migraine attacks and HIT-6 (Headache Impact Test) rating as well as in monthly intake of rescue medication (p < 0.05). Finally, compliance and satisfaction to treatment and potential adverse effects related to tSNS have been evaluated. Between run-in and second month of tSNS treatment, both primary and secondary endpoints were met. Indeed, we observed a statistically significant decrease in the frequency of migraine attacks (p < 0.001) and migraine days (p < 0.001) per month. We also demonstrated at least 50 % reduction of monthly migraine attacks and migraine days in respectively 81 and 75 % of patients. Furthermore, a statistically significant reduction in average of pain intensity during migraine attacks (p = 0.002) and HIT-6 rating (p < 0.001) and intake of rescue medication (p < 0.001) has been shown. All patients showed good compliance levels and no relevant adverse events. In patients experiencing a low frequency of attacks, significant improvements in multiple migraine severity parameters were observed following a brief period of high frequency tSNS. Therefore, tSNS may be considered a valid option for the preventive treatment of migraine attacks in patients who cannot or are not willing to take daily medications, or in whom low migraine frequency and/or intensity would not require pharmacological preventive therapies.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ethiopia 1 1%
Unknown 78 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 16%
Other 11 14%
Student > Bachelor 7 9%
Student > Ph. D. Student 6 8%
Student > Postgraduate 4 5%
Other 12 15%
Unknown 26 33%
Readers by discipline Count As %
Medicine and Dentistry 17 22%
Neuroscience 9 11%
Psychology 7 9%
Biochemistry, Genetics and Molecular Biology 5 6%
Nursing and Health Professions 4 5%
Other 9 11%
Unknown 28 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2016.
All research outputs
#846,366
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#84
of 1,417 outputs
Outputs of similar age
#10,926
of 266,065 outputs
Outputs of similar age from The Journal of Headache and Pain
#2
of 23 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,065 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.